In addition, selected patients with very high LDL-C levels (>3.4 mmol/L) or familiar hypercholesterolemia can be administered upfront combined lipid-lowering medications including ezetimibe or a PCSK9 inhibitor [10,27]. Here, PCSK9 is linked to familial hypercholesterolemia.